{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:58:16Z","timestamp":1793995096179,"version":"4.8.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Patients with very early-onset inflammatory bowel disease (VEO-IBD), with an age of onset\u2005&amp;lt;\u20056 years, can present with severe manifestations and may require biologic therapy. Infliximab and adalimumab are approved for induction and maintenance in pediatric IBD patients but are licensed only above the age of 6 years. Effectiveness and safety data on adalimumab in this patient population are lacking. We assessed the therapeutic response to help close this gap.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study involved 30 sites worldwide. Demographic, clinical, and laboratory data were collected from patients with VEO-IBD who commenced adalimumab therapy before the age of 6 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy-eight patients (37 Crohn\u2019s disease, 26 ulcerative colitis, and 15 with IBD-unclassified) were included. Median age of IBD onset was 2.6 (1.3\u20134.1) years, with 30 (38.5%) patients diagnosed at age &amp;lt;2 years. Median age at adalimumab initiation was 4.2 (2.8-5.1) years. Adalimumab was used as second-line biologic therapy in 45 (57.7%) patients after infliximab. The median time to last follow-up was 63 (22-124) weeks. Significant improvement in clinical scores, CRP, fecal calprotectin, and weight Z-score were observed by Week 52. Adalimumab durability rates were 61.9%, 48.1%, and 35.6% after 1, 2, and 3 years, respectively. Drug discontinuation rates were not dependent on IBD type, age, prior anti-TNF exposure, or concomitant immunomodulatory treatment. Four (5.1%) patients developed serious infections, including 1 patient with TTC7A deficiency who died following adenovirus sepsis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Adalimumab therapy is a viable therapeutic option in patients with VEO-IBD with an acceptable safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izae302","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T07:23:13Z","timestamp":1733728993000},"page":"2184-2194","source":"Crossref","is-referenced-by-count":6,"title":["Effectiveness and Safety of Adalimumab in Patients With Very Early-Onset Inflammatory Bowel Disease: A Retrospective Study on Behalf of the Porto Inflammatory Bowel Disease Working Group of European Society for Pediatric Gastroenterology Hepatology and Nutrition"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9748-2872","authenticated-orcid":false,"given":"Yael","family":"Weintraub","sequence":"first","affiliation":[{"name":"Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children\u2019s Medical Center of Israel , Petach Tikva 4920235 ,","place":["Israel"]},{"name":"Faculty of Medicine & Health Sciences, Tel Aviv University , Tel Aviv 6997801 ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7769-8123","authenticated-orcid":false,"given":"Lauren V","family":"Collen","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics Boston Children\u2019s Hospital and Harvard Medical School , Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9362-0465","authenticated-orcid":false,"given":"Seamus","family":"Hussey","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, University of Medicine and Health Sciences , RCSI, Dublin 2 ,","place":["Ireland"]},{"name":"Department of Paediatrics, University College Dublin , Dublin 4 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Mitrova","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, 2nd Faculty of Medicine, Charles University and University Hospital Motol , 150 06 Prague ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S","family":"Machta","sequence":"additional","affiliation":[{"name":"Paediatric Gastroenterology, Royal London Children\u2019s Hospital, Barts Health NHS Trust , London, E1 1FR ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine, Kyungpook National University , Daegu 41566 ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Granot","sequence":"additional","affiliation":[{"name":"Faculty of Medicine & Health Sciences, Tel Aviv University , Tel Aviv 6997801 ,","place":["Israel"]},{"name":"Pediatric Gastroenterology and Nutrition Unit, Edmond and Lily Safra Children\u2019s Hospital, Sheba Medical Center , Tel Hashomer, Ramat Gan 5262100 ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"D\u2019Arcangelo","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health Pediatric Gastroenterology and Liver Unit, Sapienza University of Rome\u2014Umberto I Hospital , 00185 Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6787-1164","authenticated-orcid":false,"given":"Elizabeth A","family":"Spencer","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine, Mount Sinai, Division of Pediatric Gastroenterology & Nutrition, Department of Pediatrics , New York, NY 10029 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9170-8415","authenticated-orcid":false,"given":"Kaija-Leena","family":"Kolho","sequence":"additional","affiliation":[{"name":"Department of Pediatric Gastroenterology, Children\u2019s Hospital, University of Helsinki and HUS , 00290 Helsinki ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pai-Jui","family":"Yeh","sequence":"additional","affiliation":[{"name":"Translational Gastroenterology Unit, University of Oxford , Oxford, OX1 2JD ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Sladek","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Gastroenterology and Nutrition, University Children\u2019s Hospital, Jagiellonian University Medical College , 31-008 Cracow ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1056-4400","authenticated-orcid":false,"given":"Luca","family":"Scarallo","sequence":"additional","affiliation":[{"name":"Gastroenterology and Nutrition Unit, Meyer Children\u2019s Hospital IRCCS , 50139 Florence ,","place":["Italy"]},{"name":"Department of NEUROFARBA, University of Florence , 50121 Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Palomino","sequence":"additional","affiliation":[{"name":"Gastroenterology and Nutrition Department, Hospital Infantil Universitario Nin\u0303o Jesu\u0301s , 28009 Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeem Ahmad","family":"Afzal","sequence":"additional","affiliation":[{"name":"Department of Paediatric Gastroenterology, Southampton Children\u2019s Hospital , Southampton, SO16 6YD ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"de Laffolie","sequence":"additional","affiliation":[{"name":"General Pediatrics & Pediatric Gastroenterology, Justus Liebig University , 35390 Giessen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erasmo","family":"Miele","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Science, Section of Pediatrics, University of Naples \u201cFederico II,\u201d 80131 Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5249-8248","authenticated-orcid":false,"given":"Matteo","family":"Bramuzzo","sequence":"additional","affiliation":[{"name":"Institute for Maternal and Child Health, IRCCS \u201cBurlo Garofolo ,\u201d 34137 Trieste ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Ole\u0301n","sequence":"additional","affiliation":[{"name":"Division of Clinical Epidemiology, Department of Medicine Sona, Karolinska Institutet , 171 76 Stockholm ,","place":["Sweden"]},{"name":"Pediatric Gastroenterology and Nutrition Unit, Sachs\u2019 Children\u2019s Hospital , 171 77 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard K","family":"Russell","sequence":"additional","affiliation":[{"name":"Department of Paediatric Gastroenterology, Royal Hospital for Children and Young People , Edinburgh, EH16 4TJ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pejman","family":"Rohani","sequence":"additional","affiliation":[{"name":"Pediatric Gastroenterology and Hepatology Research Center, Children\u2019s Medical Center, Pediatrics Center of Excellence, Tehran University of Medical Sciences , 14197 33151 Tehran ,","place":["Islamic Republic of Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Tzivinikos","sequence":"additional","affiliation":[{"name":"Paediatric Gastroenterology Department, Al Jalila Children\u2019s Specialty Hospital, Mohammed Bin Rashid University, Dubai Medical College , Dubai ,","place":["United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7297-538X","authenticated-orcid":false,"given":"Darja","family":"Urlep","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Nutrition, Children\u2019s Hospital, University Medical Centre Ljubljana , 1000 Ljubljana ,","place":["Slovenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick F","family":"van Rheenen","sequence":"additional","affiliation":[{"name":"Department of Paediatric Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen , 9713 GZ Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lissy","family":"de Ridder","sequence":"additional","affiliation":[{"name":"Department of Paediatric Gastroenterology, Erasmus University Medical Center, Sophia Children\u2019s Hospital , 3015 GD Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dotan","family":"Yogev","sequence":"additional","affiliation":[{"name":"Juliet Keidan Institute of Pediatric Gastroenterology and Nutrition, Shaare Zedek Medical Center , Jerusalem 9103102 ,","place":["Israel"]},{"name":"Faculty of Medicine, The Hebrew University of Jerusalem , Jerusalem 9190500 ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6116-5517","authenticated-orcid":false,"given":"Anna-Maria","family":"Schneider","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Paracelsus Medical University , Salzburg, 5020 ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6190-3217","authenticated-orcid":false,"given":"Shlomi","family":"Cohen","sequence":"additional","affiliation":[{"name":"Faculty of Medicine & Health Sciences, Tel Aviv University , Tel Aviv 6997801 ,","place":["Israel"]},{"name":"Pediatric Gastroenterology Institute, Dana-Dwek Children\u2019s Hospital, Tel Aviv Sourasky Medical Center , Tel Aviv 64239 ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Garcia-Romero","sequence":"additional","affiliation":[{"name":"Pediatric Gastroenterology and Nutrition Unit, Miguel Servet Hospital , 50009 Zaragoza ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Dipasquale","sequence":"additional","affiliation":[{"name":"Pediatric Gastroenterology and Cystic Fibrosis Unit, Department of Human Pathology in Adulthood and Childhood \u201cG. Barresi,\u201d University Hospital \u201cG. Martino,\u201d 98124 Messina ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holm H","family":"Uhlig","sequence":"additional","affiliation":[{"name":"Translational Gastroenterology Unit, University of Oxford , Oxford, OX1 2JD ,","place":["UK"]},{"name":"National Institute for Health and Care Research (NIHR) Oxford Biomedical Research Centre , Oxford, OX3 9DU ,","place":["UK"]},{"name":"Department of Pediatrics, University of Oxford , Oxford, OX3 9DU ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5980-2954","authenticated-orcid":false,"given":"Dror S","family":"Shouval","sequence":"additional","affiliation":[{"name":"Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children\u2019s Medical Center of Israel , Petach Tikva 4920235 ,","place":["Israel"]},{"name":"Faculty of Medicine & Health Sciences, Tel Aviv University , Tel Aviv 6997801 ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"issue":"27","key":"2025081217440768300_CIT0001","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1056\/NEJMra2002697","article-title":"Pathophysiology of inflammatory bowel diseases","volume":"383","author":"Chang","year":"2020","journal-title":"N Engl J Med."},{"issue":"1","key":"2025081217440768300_CIT0002","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/ibd.21349","article-title":"Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends","volume":"17","author":"Benchimol","year":"2011","journal-title":"Inflamm Bowel Dis."},{"issue":"4","key":"2025081217440768300_CIT0003","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1053\/j.gastro.2021.12.282","article-title":"Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: systematic review","volume":"162","author":"Kuenzig","year":"2022","journal-title":"Gastroenterology."},{"issue":"5","key":"2025081217440768300_CIT0004","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1053\/j.gastro.2014.07.023","article-title":"The diagnostic approach to monogenic very early onset inflammatory bowel disease","volume":"147","author":"Uhlig","year":"2014","journal-title":"Gastroenterology."},{"issue":"6","key":"2025081217440768300_CIT0005","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/ibd\/izz259","article-title":"Very early onset inflammatory bowel disease: a clinical approach with a focus on the role of genetics and underlying immune deficiencies","volume":"26","author":"Ouahed","year":"2020","journal-title":"Inflamm Bowel Dis."},{"issue":"6","key":"2025081217440768300_CIT0006","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1093\/ibd\/izz214","article-title":"The unique disease course of children with very early onset-inflammatory bowel disease","volume":"26","author":"Kelsen","year":"2020","journal-title":"Inflamm Bowel Dis."},{"issue":"3","key":"2025081217440768300_CIT0007","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1053\/j.gastro.2021.11.014","article-title":"An integrated taxonomy for monogenic inflammatory bowel disease","volume":"162","author":"Bolton","year":"2022","journal-title":"Gastroenterology."},{"issue":"8","key":"2025081217440768300_CIT0008","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1053\/j.gastro.2020.02.023","article-title":"Prevalence and clinical features of inflammatory bowel diseases associated with monogenic variants, identified by whole-exome sequencing in 1000 children at a single center","volume":"158","author":"Crowley","year":"2020","journal-title":"Gastroenterology."},{"issue":"1","key":"2025081217440768300_CIT0009","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/ecco-jcc\/jjw118","article-title":"Phenotypic and genotypic characterisation of inflammatory bowel disease presenting before the age of 2 years","volume":"11","author":"Kammermeier","year":"2017","journal-title":"J Crohns Colitis."},{"issue":"9","key":"2025081217440768300_CIT0010","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1093\/ecco-jcc\/jjy068","article-title":"Diagnostic yield of next-generation sequencing in very early-onset inflammatory bowel diseases: a Multicentre Study","volume":"12","author":"Charbit-Henrion","year":"2018","journal-title":"J Crohns Colitis."},{"issue":"9","key":"2025081217440768300_CIT0011","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/ecco-jcc\/jjac045","article-title":"Clinical phenotypes and outcomes in monogenic versus non-monogenic very early onset inflammatory bowel disease","volume":"16","author":"Collen","year":"2022","journal-title":"J Crohns Colitis."},{"issue":"3","key":"2025081217440768300_CIT0012","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn\u2019s disease in children","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology."},{"issue":"2","key":"2025081217440768300_CIT0013","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1053\/j.gastro.2012.04.046","article-title":"Safety and efficacy of adalimumab for moderate to severe Crohn\u2019s disease in children","volume":"143","author":"Hyams","year":"2012","journal-title":"Gastroenterology."},{"issue":"8","key":"2025081217440768300_CIT0014","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/S2468-1253(21)00142-4","article-title":"Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study","volume":"6","author":"Croft","year":"2021","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"3","key":"2025081217440768300_CIT0015","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1097\/MIB.0000000000001021","article-title":"Long-term efficacy and safety of Adalimumab in pediatric patients with Crohn\u2019s disease","volume":"23","author":"Faubion","year":"2017","journal-title":"Inflamm Bowel Dis."},{"issue":"1","key":"2025081217440768300_CIT0016","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1136\/gutjnl-2020-322339","article-title":"First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn\u2019s disease: an open-label multicentre randomised controlled trial","volume":"71","author":"Jongsma","year":"2022","journal-title":"Gut."},{"issue":"6","key":"2025081217440768300_CIT0017","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1097\/MIB.0000000000001075","article-title":"Growth improvement with Adalimumab treatment in children with moderately to severely active Crohn\u2019s disease","volume":"23","author":"Walters","year":"2017","journal-title":"Inflamm Bowel Dis."},{"issue":"2","key":"2025081217440768300_CIT0018","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/ecco-jcc\/jjab140","article-title":"Impact of drug approval pathways for paediatric inflammatory bowel disease","volume":"16","author":"Crowley","year":"2022","journal-title":"J Crohns Colitis."},{"issue":"9","key":"2025081217440768300_CIT0019","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1093\/ibd\/izad196","article-title":"Efficacy and safety of anti-tumor necrosis factor alpha in very early onset inflammatory bowel disease","volume":"30","author":"Collen","year":"2023","journal-title":"Inflamm Bowel Dis."},{"issue":"1","key":"2025081217440768300_CIT0020","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/MPG.0000000000003464","article-title":"Utilization of antitumor necrosis factor biologics in very early onset inflammatory bowel disease: a multicenter retrospective cohort study from North America","volume":"75","author":"Kerur","year":"2022","journal-title":"J Pediatr Gastroenterol Nutr."},{"issue":"4","key":"2025081217440768300_CIT0021","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1097\/MPG.0000000000002832","article-title":"Therapeutic drug monitoring-guided high-dose infliximab for infantile-onset inflammatory bowel disease: a case series","volume":"71","author":"Assa","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr."},{"issue":"6","key":"2025081217440768300_CIT0022","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1097\/MPG.0000000000000239","article-title":"ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents","volume":"58","author":"Levine","year":"2014","journal-title":"J Pediatr Gastroenterol Nutr."},{"issue":"2","key":"2025081217440768300_CIT0023","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/ecco-jcc\/jjaa161","article-title":"The medical management of paediatric Crohn\u2019s disease: an ECCO-ESPGHAN guideline update","volume":"15","author":"van Rheenen","year":"2020","journal-title":"J Crohns Colitis."},{"issue":"7","key":"2025081217440768300_CIT0024","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1136\/gutjnl-2019-320022","article-title":"25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future","volume":"70","author":"D\u2019Haens","year":"2021","journal-title":"Gut."},{"issue":"Suppl 1","key":"2025081217440768300_CIT0025","first-page":"S75","article-title":"Efficacy of infliximab and adalimumab therapy in very early onset, severe ulcerative colitis","volume":"14","author":"Rohani","year":"2021","journal-title":"Gastroenterol Hepatol Bed Bench."},{"issue":"4","key":"2025081217440768300_CIT0026","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/MPG.0000000000003551","article-title":"Progression to anti-TNF treatment in very early onset inflammatory bowel disease patients","volume":"75","author":"Eindor-Abarbanel","year":"2022","journal-title":"J Pediatr Gastroenterol Nutr."},{"issue":"12","key":"2025081217440768300_CIT0027","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1007\/s00431-020-03750-0","article-title":"Infliximab in young paediatric IBD patients: it is all about the dosing","volume":"179","author":"Jongsma","year":"2020","journal-title":"Eur J Pediatr."},{"issue":"9","key":"2025081217440768300_CIT0028","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/j.cgh.2022.08.011","article-title":"Effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases: the REMSWITCH Study","volume":"21","author":"Buisson","year":"2023","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"7","key":"2025081217440768300_CIT0029","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","article-title":"Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology."},{"issue":"3","key":"2025081217440768300_CIT0030","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00228-023-03613-1","article-title":"Efficacy and safety of adalimumab in pediatric patients with Crohn\u2019s disease: a systematic review and meta-analysis","volume":"80","author":"Chen","year":"2024","journal-title":"Eur J Clin Pharmacol."},{"issue":"4","key":"2025081217440768300_CIT0031","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1053\/j.gastro.2019.06.003","article-title":"Proactive monitoring of Adalimumab trough concentration associated with increased clinical remission in children with Crohn\u2019s disease compared with reactive monitoring","volume":"157","author":"Assa","year":"2019","journal-title":"Gastroenterology."},{"issue":"6","key":"2025081217440768300_CIT0032","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S2468-1253(24)00044-X","article-title":"Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn\u2019s disease: 3-year data from the prospective, multicentre PANTS cohort study","volume":"9","author":"Chanchlani","year":"2024","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"3","key":"2025081217440768300_CIT0033","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1093\/ibd\/izaa080","article-title":"Natural history of very early onset inflammatory bowel disease in North America: a retrospective cohort study","volume":"27","author":"Kerur","year":"2021","journal-title":"Inflamm Bowel Dis."},{"issue":"2","key":"2025081217440768300_CIT0034","doi-asserted-by":"publisher","first-page":"e2023064546","DOI":"10.1542\/peds.2023-064546","article-title":"Infantile and very early onset inflammatory bowel disease: a Multicenter Study","volume":"154","author":"Guz-Mark","year":"2024","journal-title":"Pediatrics."},{"issue":"3","key":"2025081217440768300_CIT0035","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1159\/000507570","article-title":"A multicenter prospective survey on early-onset inflammatory bowel disease in Japan","volume":"102","author":"Kudo","year":"2021","journal-title":"Digestion."},{"issue":"10","key":"2025081217440768300_CIT0036","doi-asserted-by":"publisher","first-page":"704","DOI":"10.7326\/M13-2403","article-title":"Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis","volume":"160","author":"Danese","year":"2014","journal-title":"Ann Intern Med."},{"issue":"7","key":"2025081217440768300_CIT0037","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/apt.12644","article-title":"Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis","volume":"39","author":"Stidham","year":"2014","journal-title":"Aliment Pharmacol Ther."},{"issue":"10","key":"2025081217440768300_CIT0038","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1136\/gutjnl-2021-326390","article-title":"Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis","volume":"71","author":"Burr","year":"2021","journal-title":"Gut."},{"issue":"6","key":"2025081217440768300_CIT0039","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1093\/ecco-jcc\/jjab208","article-title":"Differential serum-intestinal dynamics of infliximab and adalimumab in inflammatory bowel disease patients","volume":"16","author":"Bar-Yoseph","year":"2022","journal-title":"J Crohns Colitis."},{"issue":"6","key":"2025081217440768300_CIT0040","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1097\/MPG.0000000000000533","article-title":"Infliximab therapy in pediatric patients 7 years of age and younger","volume":"59","author":"Kelsen","year":"2014","journal-title":"J Pediatr Gastroenterol Nutr."},{"issue":"12","key":"2025081217440768300_CIT0041","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1097\/MIB.0000000000000212","article-title":"Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study","volume":"20","author":"Dotan","year":"2014","journal-title":"Inflamm Bowel Dis."},{"issue":"6","key":"2025081217440768300_CIT0042","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1177\/2050640619847592","article-title":"Efficacy and safety of infliximab in very early onset inflammatory bowel disease: a national comparative retrospective study","volume":"7","author":"Bramuzzo","year":"2019","journal-title":"United European Gastroenterol J."},{"issue":"12","key":"2025081217440768300_CIT0043","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s41575-023-00838-4","article-title":"Precision medicine in monogenic inflammatory bowel disease: proposed mIBD REPORT standards","volume":"20","author":"Uhlig","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"4","key":"2025081217440768300_CIT0044","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/jpn3.12147","article-title":"Catalyzing change: implementing standardised reporting in monogenic inflammatory bowel disease research","volume":"78","author":"Yeh","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"2025081217440768300_CIT0045","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s10875-022-01236-2","article-title":"A Case of XIAP deficiency successfully managed with Tadekinig Alfa (rhIL-18BP)","volume":"42","author":"Geerlinks","year":"2022","journal-title":"J Clin Immunol."},{"issue":"4","key":"2025081217440768300_CIT0046","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1053\/j.gastro.2019.11.019","article-title":"Drug Screen identifies leflunomide for treatment of inflammatory bowel disease caused by TTC7A deficiency","volume":"158","author":"Jardine","year":"2020","journal-title":"Gastroenterology."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izae302\/61444485\/izae302.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/8\/2184\/61444485\/izae302.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/8\/2184\/61444485\/izae302.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T21:44:12Z","timestamp":1755035052000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/31\/8\/2184\/7954627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":46,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,1,15]]},"published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izae302","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,1,15]]}}}